ARS Pharmaceuticals to Meet With FDA on Neffy Rejection
By Colin Kellaher
ARS Pharmaceuticals will meet later this month with the U.S. Food and Drug Administration to discuss the agency's rejection of the biopharmaceutical company's proposed epinephrine nasal spray for the treatment of severe allergic reaction.
In a surprise move last month, the FDA declined to approve the spray, which ARS plans to market as "neffy," despite a positive recommendation from one of the agency's advisory committees.
ARS on Friday said the FDA has scheduled a Type A meeting to discuss the contents of the complete response letter the agency issued on the neffy application, including its call for the San Diego company to complete a repeat-dose study prior to approval.
According to FDA guidelines, Type A meetings are aimed at resolving disputes and helping stalled product development programs proceed, with scheduling targeted to occur within 30 days of receipt of a written request.
Following the positive advisory panel in May, the FDA had been expected to approve neffy as the first needle-free epinephrine product for severe allergic reactions.
ARS last month said it had previously reached alignment with the FDA on conducting the repeat-dose study after approval of neffy, and that it planned to dispute the agency's decision.
The company on Friday said it is moving rapidly to conduct the repeat-dose study, adding that the meeting will provide an opportunity to discuss the FDA's position and a pathway forward for neffy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 06, 2023 09:42 ET (13:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk